Question to the Department of Health and Social Care:

To ask Her Majesty's Government how much Evusheld monoclonal antibody treatment they have secured; and when this treatment will be available to the clinically vulnerable in the UK.

Evusheld is not currently authorised for use in the United Kingdom. We continue to monitor a range of products, including Evusheld. However, we are unable to provide information on negotiations with companies as this is commercially sensitive.

On 5 October 2021, the Department invited suppliers to submit an expression of interest on neutralising antibody treatments being developed for treating and preventing COVID-19. This will enable the Department to undertake fair and transparent market engagement with suppliers.